Foghorn Therapeutics Inc. (FHTX)
Develops cancer medicines that target genetic vulnerabilities in tumor cells.
$5.19-0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+4.0%
The outlook
FHTX trades at $5.19, sitting above both its 50- and 200-day moving averages and roughly midway through its 52-week range. Analysts are strongly bullish with a consensus rating of 1.1 (on a scale where lower is more bullish), and their average price target implies roughly 121% upside from current levels. The overall sentiment leans decidedly positive based on current analyst views and technical positioning.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 9 analysts
Price trendAbove its 50- & 200-day averages
52-week range52% of the way from its 52-week low to high
Price targetAvg target +121% vs current price
Analyst price target
~12-month · 9 analysts$11.44average target+120.5% vs now
Now $5.19
Low $9.00High $14.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$304.7M
52-wk high
$6.95
52-wk low
$3.27
50-day avg
$4.53
200-day avg
$4.87
Trailing P/E
—